Iterative Mapping of proteoforms provides insights into proteoform complexity at the single-molecule level, with implications for understanding protein regulation in neurodegenerative diseases and beyond.
Abstract
Proteins exist as diverse proteoforms resulting from a combination of genetic variation, alternative splicing and post-translational modifications. Current methods struggle to capture this complexity at the single-molecule level. Here we introduce Iterative Mapping of proteoforms, a method that enables massively parallel interrogation of millions to billions of single-protein molecules through iterative probing with fluorescently labeled antibodies. We applied Iterative Mapping to tau, a key protein in neurodegenerative diseases, using 12 site-specific antibodies. The tau proteoform assay demonstrates high sensitivity (detecting proteoforms at 0.1% abundance), high reproducibility (median coefficient of variation <5.5%) and broad dynamic range (>3 orders of magnitude), outperforming conventional techniques in resolving closely related proteoform groups. Analysis of relevant biological samples, including organoids, mouse brains and human Alzheimer’s disease samples, revealed 130 distinct tau proteoform groups with as many as six phosphorylation events. The nonrandom distribution of these phosphorylation events suggests ordered and site-specific modification processes rather than random, stochastic accumulation. Iterative Mapping provides insights into proteoform complexity at the single-molecule level, with implications for understanding protein regulation in neurodegenerative diseases and beyond. Iterative Mapping of proteoforms enables large-scale measurement of intact proteoforms with single-molecule resolution. The approach is demonstrated here by quantifying tau proteoform groups across control samples of known composition, model systems used in tauopathy research, and human-derived brain tissue samples.
The evolving role of TDP in biomedical research is reviewed, highlighting studies that revealed proteoform-level alterations, identified candidate biomarkers, and advanced the understanding of the roles of proteoforms in human diseases.
Holden T. Rogers, Z. Gregorich, Megan S. Gant et al.· Mass spectrometry reviews (P...· 1 citation
Improvements enabling quantification of site-specific modifications, including post-translational modifications and covalent compound-protein interactions spanning diverse pathways are described.
Steven R. Shuken, Geordon A. Frere, Charlotte R. Beard et al.· Nature Communications· 0 citations
A protein corona-based secretome profiling strategy is developed and incorporated into a multiomics analytical framework, enabling secretome profiling in a model that better preserves tumor heterogeneity and microenvironmental context and establishes a robust and scalable strategy for incorporating the secretome into m...
Cai-Wei Hu, Jia-Liang Zhao, Qian Li et al.· Analytical Chemistry· 0 citations
A proteoform-by-environment model for IDP structure is established, in which phosphorylation effects are not fixed but are rewritten by the surrounding chemical environment, which distinguishes broad contact accessibility from the residue-level contacts that dominate each condition.
Ashlyn N. Dollar, Daniel W. Kelley, Ian K. Webb· Journal of the American Chem...· 0 citations
A recurrent AML dark proteome is defined and a framework for the discovery of tumor-specific non-canonical proteins for mechanistic and therapeutic studies is established.
L. Schmalbrock, Asher Preska Steinberg, Katarzyna Kulej et al.· bioRxiv· 0 citations